Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome

Interregional Clinical Diagnostic Center, Russia

Status: Completed

Conditions: Pelvic Congestion Syndrome

Treatments: Drug: Daflon

Study type: Observational

Funder types: Other

Identifiers

NCT04512443

Daflon25122019

Details and patient eligibility

About

The article presents the results of a randomized, placebo-controlled study of the conservative treatment with Daflon (Detralex) in female patients with Pelvic congestion syndrome .

Enrollment: 83 patients

Sex: Female

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

•The presence of pelvic varicose veins verified by transvaginal and transabdominal duplex ultrasound scanning

Exclusion criteria

• Severe disease of the gastrointestinal tract or hematopoietic system
• Terminal stage of cardiovascular, respiratory, renal or hepatic failure
• Grade IV malignancy
• Peripheral artery disease (PAD) of the lower extremities, any type of diabetes, or mental disease.
• Pregnant women at any gestational age, women who gave birth less than 12 months ago, and breastfeeding mothers.

Trial design

83 participants in 2 patient groups

1

Description:

42 women (treated with Daflon 1000 mg (study group))

Treatment:

Drug: Daflon

2

Description:

41 women (placebo (control group))